[go: up one dir, main page]

UY24512A1 - Desnaturalizantes de sales de amina simpatomimeticas - Google Patents

Desnaturalizantes de sales de amina simpatomimeticas

Info

Publication number
UY24512A1
UY24512A1 UY24512A UY24512A UY24512A1 UY 24512 A1 UY24512 A1 UY 24512A1 UY 24512 A UY24512 A UY 24512A UY 24512 A UY24512 A UY 24512A UY 24512 A1 UY24512 A1 UY 24512A1
Authority
UY
Uruguay
Prior art keywords
amine salt
denaturalizers
sympathomimetic amine
sympathomimetic
amine
Prior art date
Application number
UY24512A
Other languages
English (en)
Inventor
Nichols Bess Y Lech
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY24512A1 publication Critical patent/UY24512A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige al agregado de uno o más denaturnates farmacéuticamente y biológicamente aceptables a productos farmacéuticos que contienen sal de amina simpatomimética, para hacer que esos productos sean menos apropiados de drogas ilegales. En una configuración preferida, el denaturantes y la sal de amina simpatomimétrica muestran propiedades químicas y físicas similares, de manera que la purificación de amina simpatomimética mediante técnicas convencionales de extracción se hace difícil o esencialmente imposible.
UY24512A 1996-04-10 1997-04-09 Desnaturalizantes de sales de amina simpatomimeticas UY24512A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1523996P 1996-04-10 1996-04-10
US3260296P 1996-12-11 1996-12-11
US4055097P 1997-03-13 1997-03-13

Publications (1)

Publication Number Publication Date
UY24512A1 true UY24512A1 (es) 2001-08-27

Family

ID=27360291

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24512A UY24512A1 (es) 1996-04-10 1997-04-09 Desnaturalizantes de sales de amina simpatomimeticas

Country Status (18)

Country Link
US (1) US6136864A (es)
EP (1) EP0894010B1 (es)
JP (1) JP2001527514A (es)
AR (1) AR006571A1 (es)
AT (1) ATE244019T1 (es)
BR (1) BR9708559A (es)
CA (1) CA2250010C (es)
DE (1) DE69723248T2 (es)
DK (1) DK0894010T3 (es)
ES (1) ES2202605T3 (es)
MX (1) MX9807594A (es)
NZ (1) NZ332233A (es)
PE (1) PE20011304A1 (es)
PT (1) PT894010E (es)
SI (1) SI0894010T1 (es)
TW (1) TW522012B (es)
UY (1) UY24512A1 (es)
WO (1) WO1997037689A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
GT199900148A (es) 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
JP4370451B2 (ja) * 2001-09-28 2009-11-25 大塚製薬株式会社 医薬組成物
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
DK1765292T3 (en) 2004-06-12 2018-01-02 Collegium Pharmaceutical Inc ABUSE PREVENTIONAL PHARMACEUTICAL FORMULATIONS
DE102004045037A1 (de) * 2004-09-15 2006-03-16 Basf Ag Pharmazeutische Darreichungsformen mit erschwerter Extrahierbarkeit eines Sympathomimetikums aus der Darreichungsform
US9238073B2 (en) * 2006-04-12 2016-01-19 Wyeth Llc Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
CA2689434C (en) * 2007-06-04 2017-09-26 Shear/Kershman Laboratories, Inc. Tamper resistant lipid-based oral dosage form for opioid agonists
WO2011041414A1 (en) * 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2991217C (en) 2010-12-22 2020-06-09 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
US20150238615A1 (en) * 2011-12-12 2015-08-27 Leonard Mackles Denaturants for sympathomimetic amines
EP2925304B1 (en) 2012-11-30 2018-09-05 Acura Pharmaceuticals, Inc. Self-regulated release of active pharmaceutical ingredient
EP2953618B1 (en) 2013-02-05 2020-11-11 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JP6510628B2 (ja) 2014-03-26 2019-05-15 サン・ファーマ・アドバンスト・リサーチ・カンパニー・リミテッド 乱用防止即時放出性被覆リザーバ固体剤形
US10058490B2 (en) * 2014-12-24 2018-08-28 L'oreal Acoustically-activated cosmetic hydrogels
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
FR3059903B1 (fr) * 2016-12-08 2019-03-22 Salsarulo Pharma Medicament oral comprenant un laxatif osmotique incorpore dans une matrice a base de matieres grasses vegetales
CN114073690B (zh) * 2020-08-10 2024-01-12 江苏长泰药业有限公司 一种含有氨基酸的防提取药物组合物及其制剂
CN114073689B (zh) * 2020-08-10 2024-01-12 江苏长泰药业有限公司 一种防提取药物组合物及其制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3169092A (en) * 1963-09-26 1965-02-09 Richardson Merrell Inc Stabilization of amines by tartrazine and bisulfite
US3773920A (en) * 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
GB1593261A (en) * 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
US4493827A (en) * 1983-11-14 1985-01-15 Ronald Valle Method of inducing sleep
US4657757A (en) * 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4689223A (en) * 1986-04-24 1987-08-25 T & R Chemicals, Inc. Method of treating the symptoms of the common cold
ZA904021B (en) * 1989-11-24 1991-02-27 Van Der Linde Leon Slimming preparations
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
NZ267002A (en) * 1993-06-04 1997-07-27 Warner Lambert Co Chewable cold/sinus relief preparation comprising antihistamine and decongestant in a carrier consisting of silicon dioxide
AUPM814994A0 (en) * 1994-09-14 1994-10-06 Sterling Winthrop Inc. Codeine-containing formulations
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays

Also Published As

Publication number Publication date
ATE244019T1 (de) 2003-07-15
DE69723248D1 (de) 2003-08-07
SI0894010T1 (en) 2003-10-31
WO1997037689A3 (en) 1997-12-04
AR006571A1 (es) 1999-09-08
AU2436097A (en) 1997-10-29
MX9807594A (en) 1999-03-31
AU711752B2 (en) 1999-10-21
PT894010E (pt) 2003-11-28
PE20011304A1 (es) 2002-01-18
BR9708559A (pt) 1999-08-03
JP2001527514A (ja) 2001-12-25
DE69723248T2 (de) 2004-05-27
WO1997037689A2 (en) 1997-10-16
DK0894010T3 (da) 2003-10-27
TW522012B (en) 2003-03-01
ES2202605T3 (es) 2004-04-01
NZ332233A (en) 1999-11-29
CA2250010A1 (en) 1997-10-16
EP0894010B1 (en) 2003-07-02
US6136864A (en) 2000-10-24
EP0894010A2 (en) 1999-02-03
CA2250010C (en) 2008-06-10

Similar Documents

Publication Publication Date Title
UY24512A1 (es) Desnaturalizantes de sales de amina simpatomimeticas
UY26320A1 (es) Sales farmaceuticas de la sustancia activa tramadol y al menos un edulcorante, medicamentos que contienen estas sales, el uso de estas sales para la preparacion de medicamentos y formas de administracion que contienen esas sales. ley 17164
BR0309544A (pt) Preparação farmacêutica contendo oxicodona e naloxona
AR064895A2 (es) Composicion farmaceutica anhidra para el tratamiento de desordenes inducidos por histamina
ID28003A (id) Turunan-turunan adamantana
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
BR0111913A (pt) Análogos de gabapentina para distúrbios do sono
KR960700054A (ko) 파킨슨씨 병 및 파킨슨 증후군의 치료에 리루졸의 이용(application of riluzole in the treatment of parkinson's disease and parkinsonian syndromes)
DK1290011T3 (da) Melphalan-derivater og deres anvendelse som cancer-kemoterapeutiske lægemidler
BR9909819A (pt) Amida, uso de amidas, e, preparação farmacêutica para uso oral, parenteral ou intraperitoneal
BR9913072A (pt) Sistemas de anel azacìclico, composição farmacêutica, e, processo para induzir a analgesia
ES2071663T3 (es) Analogo de fluoxetina.
CU22439A3 (es) Capsula de precinto para botellas y similares.
ES2171459T3 (es) Polvo para administracion nasal de farmaco peptidico o proteinaceo.
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
HUP0100611A2 (hu) Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére
CO5210869A1 (es) Una combinacion sinergetica: gabapentina y pregabalina
BR0016941A (pt) Derivados de aminometil-fenil-ciclohexanona
ES2099048T3 (es) Uso de ropivacaina en la fabricacion de un producto farmaceutico con efecto analgesico y con bloqueo motor minimo.
EA199900963A1 (ru) Лекарственные формы сертралина в виде раствора, заключенного в желатиновые капсулы
BR0210007A (pt) Uso de inibidores de il-18 para tratamento ou prevenção de lesões do sistema nervoso central
DE59811656D1 (en) Kombinationspräparat aus 2-methylthiazolidin-2,4-dicarbonsäure und paracetamol
BR9911969A (pt) Sal e processos para a preparação de um sal, para a preparação de acetato de n-terc-butilhidroxilamina, para o isolamento de acetato de n-terc- butilhidroxilamina, e para a purificação do acetato de n-terc- butilhidroxilamina
HUP0100802A2 (hu) (1S,4R)-cisz-4-[2-amino-6-(ciklopropil-amino)-9H-purin-9-il]-2-ciklopentén-1-metanolt tartalmazó új gyógyszerkészítmények
ES2192608T3 (es) Uso de derivados de alilamina tales como terbinafina, en la fabricacion de un medicamento para el tratamiento de la infeccion por helicobacter pylori de enfermedades asociadas.

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20170409